Skip to main content

Table 2 Patient characteristics stratified by warfarin use

From: Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study

Characteristic All (n = 35) Warfarin user (n = 12) Non-warfarin user (n = 23)
Age (years) 61 (51–77) 65.5 (52.5–79) 59 (51–74)
Male 25 (71%) 8 (67%) 17 (74%)
PT-INR at trough 1.39 (1.12–2.38) 2.62 (1.63–3.29) 1.19 (1.06–1.42)
Time interval between trough and peak (min) 105 (95–120) 95 (95–110) 112.5 (90–120)
Daptomycin dose (mg/kg/dose) 6.0 (5.9–6.1) 6.0 (5.9–6.4) 6.0 (5.8–6.0)
Number of daptomycin administered before peak 4 (3–5) 4.5 (4–5.5) 4 (3–5)
Creatinine clearance (mL/min) 84.8 ± 54.1 74.2 ± 40.4 89.9 ± 59.7
Source of infection
 Skin/joint infection 19 (54%) 7 (58%) 12 (52%)
 Bacteraemia 12 (34%) 5 (42%) 7 (30%)
 Other infections 4 (11%) 0 (0%) 4 (17%)
Comorbidity
 Autoimmune disease 5 (14%) 2 (17%) 3 (13%)
 Cancer 6 (17%) 2 (17%) 4 (17%)
 Cardiovascular disease 13 (37%) 8 (67%) 5 (22%)
 Others 11 (31%) 0 (0%) 11 (48%)
Concomitant antibiotic use 17 (49%) 7 (58%) 10 (43%)
  1. Data are shown as a number (%), mean ± standard deviation or median (interquartile range)
  2. PT-INR prothrombin time-international normalised ratio. PT-INR by Reagent 1 is shown